Application of Anti-Pd-L1 Monoclonal Antibody Atezolizumab in Second Line Therapy of Common Urothelial Bladder Cancer

Effective Pharmacotherapy
doi 10.33978/2307-3586-2019-15-38-30-34
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Medforum

Related search

Experience of Using Atezolizumab in 1st Line Therapy of Metastatic Urothelial Cancer

Onkourologiya
OncologyRadiologyUrologyNuclear MedicineNephrologyImagingSurgery
2019English

Rationale of Combination of Anti-Pd-1/Pd-L1 Antibody Therapy and Radiotherapy for Cancer Treatment

International Journal of Clinical Oncology
MedicineSurgeryOncologyHematology
2020English

Monoclonal Antibody L1Mab-13 Detected Human PD-L1 in Lung Cancers

Monoclonal Antibodies in Immunodiagnosis and Immunotherapy
AllergyImmunology
2018English

Complete Response to Anti-Pd-L1 Antibody in a Metastatic Bladder Cancer Associated With Novel MSH4 Mutation and Microsatellite Instability

Journal for ImmunoTherapy of Cancer
OncologyMolecular MedicinePharmacologyCancer ResearchAllergyImmunology
2020English

Atezolizumab Combo Approved for PD-L1–positive TNBC

Cancer Discovery
Oncology
2019English

Robust Antitumor Effects of Combined Anti-Cd4-Depleting Antibody and Anti-Pd-1/Pd-L1 Immune Checkpoint Antibody Treatment in Mice

Cancer immunology research
Cancer ResearchImmunology
2015English

Complement-Mediated Mechanisms in Anti-Gd2 Monoclonal Antibody Therapy of Murine Metastatic Cancer

Cancer Research
Cancer ResearchOncology
2005English

Immuno-Pet Imaging of 89Zr Labeled Anti-Pd-L1 Domain Antibody

English

NSCLC: Atezolizumab Mit Überlebensvorteil Unabhängig Vom PD-L1-Status

Pneumologie
MedicinePulmonaryRespiratory Medicine
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy